Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221–223).

The road to resistance: EGFR mutation and cetuximab

BARDELLI, Alberto;
2012-01-01

Abstract

Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221–223).
2012
Inglese
Esperti anonimi
18
2
199
200
2
STATI UNITI D'AMERICA
2
03-CONTRIBUTO IN RIVISTA::03B-Review in Rivista / Rassegna della Lett. in Riv. / Nota Critica
none
262
info:eu-repo/semantics/article
Bardelli A; Jänne PA
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/93978
Citazioni
  • ???jsp.display-item.citation.pmc??? 39
  • Scopus 59
  • ???jsp.display-item.citation.isi??? 54
social impact